This was the reply to you not long ago from me if your former ID is " tnyjax34 ".
If GEMOX(the regimen which you are having now) works like you say, I will continue the course of treatment until otherwise. You want to reserve more options for the future just in case. For me(as a patient),CC is a long war and not just a battle. You need to think far ahead of the game if God is willing to give His Grace to you and me to have that long the time frame to fight and learn about CC.
Gemox+ Cetuximab(a MoAb like bevacizumab-Avastin) have good results in objective response(63%) but long -term outcome were not reported.So when I read this article ,I ( as a patient)will think about what is next if this regimen don't work again after initial success and/or if the CC recur again for the 2nd time . The other clinical protocol is Gemzar+Xeloda+Avastin which also provided good results but side effects like colon perforation from Avastin has been reported.
In general "IF IT WORKS,DON'T FIX"
The following is my response to your current questions.
If currently your CCA is "stable" that means your CCA is currently responsible to the GEMOX treatment . Carpoplatin and cisplatin(which you had before changing to oxaliplatin because of nausea/vomiting side effects) are more or less the same because they are all belonging to the platium family .
Gemzar+ carboplatin is mainly a regimen for bladder cancer. GEM/CIS and GEM/CAP are for biliary and pancreatic cancer.
If you have peritoneal metastasis GEMOX+ Avastin may be of value since I knew it has good objective response( partial response>30% for my sister-in law's peritoneal carcinomatosis in her omentum.) She had to discontinue the Avastin due to colon perforation caused by Avastin. But every patient is different and the incidence rate for GI perforation of Avastin is <1%-4%.
Folfox is 5FU+oxaliplatin but CAPOX--CAPecitabine(a prodrug of 5FU)+ OXaliplatin may be easier for patient since Xeloda is taken by mouth. If you had extrahepatic CCA before you had the liver transplant,a phase II study of CAPOX trial of 65 patients with advance biliary cancer shown more favorable results to extra than intrahepatic CCA patients.
Of course molecularly targeted agents like Tarceva and others are among other choices if you will need them in the future.
Again, please always keep in mind that ,the addition of other drugs ,in theory, will add toxicity too. so you have to weight the benefits against the adverse effects as well. good luck and
Please know that my personal opinion is not intended nor implied to be a substitute for professional medical advice. If provided, information are for educational purposes.Consult doctor is a MUST for changing of treatment plans.